Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Nod-like receptor pyrin domain-containing 3 inflammasome (NLRP3 inflammasome) is a multiprotein complex that acts as an essential sensor within the innate immune system. It detects diverse exogenous pathogens and endogenous danger signals—such as crystalline substances, ATP release, mitochondrial dysfunction products—and responds by assembling into a supramolecular structure composed primarily of three components: NLRP3 itself; ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain), which bridges interactions; and caspase‑1, which processes pro-inflammatory cytokines like interleukin‑1β and interleukin‑18 into their active forms. Activation leads to robust inflammatory responses including pyroptotic cell death. The molecular mechanism involves detection of cellular stressors leading to potassium efflux or other triggers that promote conformational changes in NLRP3. This enables it to oligomerize with NEK7 kinase assistance at centrosomes where it recruits ASC via homotypic PYD-PYD interactions; ASC then polymerizes into filaments recruiting pro-caspase–1 through CARD-CARD interactions. Activated caspase–1 cleaves pro–IL–1β/IL–18 for secretion and gasdermin D for membrane pore formation causing pyroptosis[1][2][4][5]. Aberrant activation—often due to gain-of-function mutations—contributes directly to autoinflammatory syndromes such as CAPS but also plays roles in chronic inflammatory conditions including neurodegeneration, cardiovascular diseases like gout/atherosclerosis, diabetes complications such as impaired wound healing,[6] infection control failures,[8] among others. Because dysregulation drives pathology across multiple systems while being central to host defense mechanisms against infection/injury signals,[4] it is considered both an attractive therapeutic target—and one requiring careful modulation due to safety concerns regarding immunosuppression[5].
Drugs or molecules that inhibit or modulate the assembly/activation of the NLRP3 inflammasome typically act by blocking oligomerization of NLRP3, inhibiting its interaction with NEK7 or ASC, preventing potassium efflux, or suppressing downstream caspase‑1 activation and cytokine maturation/release.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nod-like receptor pyrin domain-containing 3 inflammasome (NLRP3 inflammasome).